FTC Closes Antitrust Probe Of Allergan's Acular Drug
The FTC's Bureau of Competition wrapped up its probe after the U.S. District Court for the Northern District of California ruled in December that the patent covering the top-selling anti-inflammatory treatment is valid and enforceable.
The district court ruled that Apotex and some of its subsidiaries would infringe on the Acular patent by producing a proposed generic version. The antitrust action was...
To view the full article, register now.